Autoimunska manifestacija infekcije virusom hepatitisa C kao rizik od kasnog virusološkog relapsa posle terapije pegilovanim interferonom i ribavirinom

  • Maja Ružić Clinical Center of Vojvodina, Clinic for Infectious Diseases, Novi Sad, Serbia
  • Milotka Fabri Clinical Center of Vojvodina, Clinic for Infectious Diseases, Novi Sad, Serbia
  • Tomislav Preveden Clinical Center of Vojvodina, Clinic for Infectious Diseases, Novi Sad, Serbia
  • Katarina Bačulov Clinical Center of Vojvodina, Center for Laboratory Medicine, Novi Sad, Serbia
  • Maria Pete Clinical Center of Vojvodina, Clinic for Infectious Diseases, Novi Sad, Serbia
  • Anja Jasna Stojšin Clinical Center of Vojvodina, Clinic for Infectious Diseases, Novi Sad, Serbia
DOI: https://doi.org/10.2298/VSP161026015R
Ključne reči: hepatitis c;, interferon alfa-2b;, ribavirin;, lečenje, ishod;, recidiv;, autoimunske bolesti.

Sažetak


Uvod. Iskustvo u lečenju hepatitis C virus (HCV) infekcije pegilovanim interferonom alfa (PegIFNa) i ribavirinom (RBV) ukazuje na postojanje rizika od kasnog virusološkog relapsa“ (late virological response – LVR) – ponovna detekcija HCV ribonukleinske kiseline (RNA) u serumu godinama nakon uspostavljanja stabilnog virušološkog odgovora – sustained virological response (SVR). Prikazana su tri bolesnika sa LVR lečena PegIFNa i ribavirinom pet godina nakon uspostavljanja SVR. Prikaz bolesnika. Analizirano je ukupno 129 bolesnika (38,8% ženskog, 61,2% muškog pola, pro­sečna starost 37,02 ± 11,99 godina) lečenih od hroničnog HCV PegIFNa + RBV, kod kojih je prošlo najmanje pet godina od uspostavljanja SVR. Pored biohemijskih parametara funkcije jetre, rađen je kvalitativni lančane reakcije polimeraze (PCR) HCV RNA test, odnosno kvantitativni PCR HCV RNA test. Pet godina od uspostavljanja SVR kod tri (2,3%) bolesnika je kvalitativnim i kvantitativnim testom PCR HCV RNA utvrđen relaps HCV infekcije. Sva tri bolesnika imala su i pridružene autoimunske bolesti: vaskulitis, autoimunski hepatitis i vaskulitis centralnog nervnog sistema. Zaključak. Potvrđeno je postojanja LVR HCV infekcije prvenstveno kod bolesnika sa pridruženim autoimunskim bolestima. Stoga SVR nakon terapije PegIFNa + RBV treba shvatiti kao pokazatelja uspešne HCV supresije, a ne potpune eradikacije HCV.

Biografija autora

Anja Jasna Stojšin, Clinical Center of Vojvodina, Clinic for Infectious Diseases, Novi Sad, Serbia

Serbia

Reference

References

Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epi¬demiology and genotype distribution of the hepatitis C vi-rus infection. J Hepatol 2014; 61(suppl 1): 45–57.

European Association for the Study of the Liver. EASL Recommen-da¬tions on Treatment of Hepatitis C. J Hepatol 2015; 63(1): 199–236.

Morisco F, Granata R, Stroffolini T, Guarino M, Donnarumma L, Gaeta L, et al. Sustained virological response: a milestone in the treatment of chronic hepatitis C. World J Gastroenterol 2013; 19(18): 2793–8.

Swain MG, Lai M, Shiffman ML, Cooksley GW, Zeuzem S, Di-eterich DT, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010; 139(5): 1593–601.

Manns MP, Pockros PJ, Norkrans G, Smith CI, Morgan TR, Häussinger D, et al. Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin. J Viral Hepat 2013; 20(8): 524–9.

Formann E, Steindl-Munda P, Hofer H, Jessner W, Bergholz U, Gur¬guta C, et al. Long-term follow-up of chronic hepatitis C pa¬tients with sustained virological response to various forms of interferon-based anti-viral therapy. Aliment Pharmacol Ther 2006; 23(4): 507–11.

George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoff-mann J, di Bisceglie AM. Clinical, virologic, histologic, and bio-chemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients. Hepatology 2009; 49(3): 729–38.

Fujii H, Itoh Y, Ohnishi N, Sakamoto M, Ohkawara T, Sawa Y, et al. Relapse of hepatitis C in a pegylated-interferon-alpha-2b plus ribavirin-treated sustained virological responder. Hepatol Res 2010; 40(6): 654–60.

Namikawa M, Kakizaki S, Yata Y, Yamazaki Y, Horiguchi N, Sato K, et al. Optimal follow-up time to determine the sus-tained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin. J Gastroenterol Hepatol 2012; 27(1): 69–75.

Radkowski M, Gallegos-Orozco JF, Jablonska J, Colby TV, Walew-ska-Zielecka B, Kubicka J, et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepa-tology 2005; 41(1): 106–14.

Pham TN, Michalak TI. Occult hepatitis C virus infection and its relevance in clinical practice. J Clin Exp Hepatol 2011; 1(3): 185–9.

Welker M, Zeuzem S. Occult hepatitis C: How convincing are the current data? Hepatology 2009; 49(2): 665–75.

Castillo I, Rodríguez-Iñigo E, López-Alcorocho JM, Pardo M, Bar-tolomé J, Carreño V. Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment. Clin Infect Dis 2006; 43(10): 1277–83.

Tsuda N, Yuki N, Mochizuki K, Nagaoka T, Yamashiro M, Omura M, et al. Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy. J Med Virol 2004; 74(3): 406–13.

Pawlotsky J. Therapy of hepatitis C: from empiricism to eradi-ca¬tion. Hepatology 2006; 43(2 Suppl 1): 207–20.

Uyanikoglu A, Kaymakoglu S, Danalioglu A, Akyuz F, Ermis F, Pi¬narbasi B, et al. Durability of sustained virologic response in chronic hepatitis C. Gut Liver 2013; 7(4): 458–61.

Marciano S, Borzi SM, Dirchwolf M, Ridruejo E, Mendizabal M, Bes¬sone F, et al. Pre-treatment prediction of response to pegin-ter¬feron plus ribavirin in chronic hepatitis C genotype 3. World J Hepatol 2015; 7(4): 703–9.

Rosen HR. Emerging concepts in immunity to hepatitis C virus infection. J Clin Invest 2013; 123(10): 4121–30.

Larrubia J, Moreno-Cubero E, Miquel J, Sanz-Villalobos E. Hepa-ti¬tis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control. World J Gastro-enterol 2015; 21(12): 3480–91.

Lin A, Thadareddy A, Goldstein MJ, Lake-Bakaar G. Immune sup¬pression leading to hepatitis C virus re-emergence after sustained virological response. J Med Virol 2008; 80(10): 1720–2.

Gordon CE, Balk EM, Becker BN, Crooks PA, Jaber BL, Johnson CA, et al. KDOQI US commentary on the KDIGO clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in CKD. Am J Kidney Dis 2008; 52(5): 811–25.

Djukanović L, Aksić-Miličević B, Antić M, Baković J, Varga Ž, Go-jaković B, et al. Epidemiology of end-stage renal disease and hemodialysis treatment in Serbia at the turn of the millenni-um. Hemodial Int 2012; 16(4): 517–25.

Cunningham EB, Applegate TL, Lloyd AR, Dore GJ, Grebely J. Mixed HCV infection and reinfection in people who inject drugs: Impact on therapy. Nat Rev Gastroenterol Hepatol 2015; 12(4): 218–30.

Objavljeno
2021/01/13
Broj časopisa
Vol. 75 Br. 12 (2018): Vojnosanit pregl
Rubrika
Prikaz bolesnika